多发性骨髓瘤CAR-T细胞治疗的耐药机制：来自2024年ASH年会上的最新消息。

IF 9.4 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2025-03-26 DOI:10.1186/s40164-025-00643-6

Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, Quande Lin

{"title":"多发性骨髓瘤CAR-T细胞治疗的耐药机制：来自2024年ASH年会上的最新消息。","authors":"Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, Quande Lin","doi":"10.1186/s40164-025-00643-6","DOIUrl":null,"url":null,"abstract":"Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"14 1","pages":"45"},"PeriodicalIF":9.4000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938694/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.\",\"authors\":\"Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, Quande Lin\",\"doi\":\"10.1186/s40164-025-00643-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.\",\"PeriodicalId\":12180,\"journal\":{\"name\":\"Experimental Hematology & Oncology\",\"volume\":\"14 1\",\"pages\":\"45\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938694/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental Hematology & Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40164-025-00643-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40164-025-00643-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体t细胞（CAR-T）疗法在多发性骨髓瘤（MM）的治疗中显示出巨大的潜力。然而，对CAR-T疗法的耐药性仍然是一个关键的挑战。研究CAR-T抵抗的潜在机制，包括抗原逃逸、免疫抑制和CAR-T细胞衰竭，对于提高这种治疗方法的长期疗效至关重要。本研究对第66届ASH年会上提出的最新研究结果进行了深入的回顾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.

Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.